Osteoclast inhibition impairs chondrosarcoma growth and bone destruction

Journal of Orthopaedic Research

Volumn 32, Issue 12, 2014, Pages 1562-1571

  Otero, Jesse E ^a   Stevens, Jeff W ^a   Malandra, Allison E ^b   Fredericks, Douglas C ^b   Odgren, Paul R ^c   Buckwalter, Joseph A ^a,d   Morcuende, Jose ^d  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bisphosphonate; Chondrosarcoma; Osteoclast; Osteolysis

Indexed keywords

ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PARATHYROID HORMONE RELATED PROTEIN; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; CANCER TRANSPLANTATION; CHONDROSARCOMA; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MALE; NONHUMAN; OSTEOCLAST; RAT; SPRAGUE DAWLEY RAT; TIBIA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BONE; ETIOLOGY; OSTEOLYSIS; PATHOLOGY; PHYSIOLOGY; PREVENTION AND CONTROL;

ANIMALS; BONE AND BONES; BONE RESORPTION; CHONDROSARCOMA; DIPHOSPHONATES; IMIDAZOLES; MALE; OSTEOCLASTS; PARATHYROID HORMONE-RELATED PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; TRANSFORMING GROWTH FACTOR BETA2;

EID: 84911805208     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22714     Document Type: Article

References (28)

1. Hameed M, Dorfman H. 2011. Primary malignant bone tumors-recent developments. Semin Diagn Pathol 28:86-101.
2. Kim MJ, Cho KJ, Ayala AG, et al. 2011. Chondrosarcoma: with updates on molecular genetics. Sarcoma 2011:405437.
3. Moussavi-Harami F, Mollano A, Martin JA, et al. 2006. Intrinsic radiation resistance in human chondrosarcoma cells. Biochem Biophys Res Commun 346:379-385.
4. Donati D, El Ghoneimy A, Bertoni F, et al. 2005. Surgical treatment and outcome of conventional pelvic chondrosar-coma. J Bone Joint Surg Br 87:1527-1530.
5. Lee FY, Mankin HJ, Fondren G, et al. 1999. Chondrosar-coma of bone: an assessment of outcome. J Bone Joint Surg Am 81:326-338.
6. Pring ME, Weber KL, Unni KK, et al. 2001. Chondrosar-coma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am 83-A:1630-1642.
7. Sheth DS, Yasko AW, Johnson ME, et al. 1996. Chondrosar-coma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer 78:745-750.
8. Pritchard DJ, Lunke RJ, Taylor WF, et al. 1980. Chondro-sarcoma: a clinicopathologic and statistical analysis. Cancer 45:149-157.
9. Wirbel RJ, Schulte M, Maier B, et al. 2000. Chondrosarcoma of the pelvis: oncologic and functional outcome. Sarcoma 4:161-168.
10. Teitelbaum SL. 2007. Osteoclasts: what do they do and how do they do it? Am J Pathol 170:427-435.
11. Hamm CA, Stevens JW, Xie H, et al. 2010. Microenviron-ment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors. BMC Cancer 10:471.
12. Breitkreutz D, Diaz de Leon L, Paglia L, et al. 1979. Histological and biochemical studies of a transplantable rat chondrosarcoma. Cancer Res 39:5093-5100.
13. Gouin F, Ory B, Redini F, et al. 2006. Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer 119:980-984.
14. Van Wesenbeeck L, Odgren PR, MacKay CA, et al. 2002. The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: evidence of a crucial role for CSF-1 in osteoclastogenesis and endochon-dral ossification. Proc Natl Acad Sci USA 99:14303-14308.
15. Morcuende JA, Stevens JW, Scheetz TE, et al. 2012. Swarm rat chondrosarcoma cells as an in vivo model: lung colonization and effects of tissue environment on tumor growth. Iowa Orthop J 32:46-53.
16. Kenan S, Steiner GC. 1991. Experimental transplantation of the Swarm rat chondrosarcoma into bone: radiological and pathological studies. J Orthop Res 9:445-451.
17. Gnant M, Mlineritsch B, Schippinger W, et al. 2009. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691.
18. Wardley A, Davidson N, Barrett-Lee P, et al. 2005. Zole-dronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 92:1869-1876.
19. Grimaud E, Damiens C, Rousselle AV, et al. 2002. Bone remodelling and tumour grade modifications induced by interactions between bone and swarm rat chondrosarcoma. Histol Histopathol 17:1103-1111.
20. Hascall GK, Kimura JH. 1981. The ultrastructure of cultures from the Swarm rat chondrosarcoma. Anat Rec 200:287-292.
21. Kimura JH, Hardingham TE, Hascall VC, et al. 1979. Biosynthesis of proteoglycans and their assembly into aggregates in cultures of chondrocytes from the Swarm rat chondrosarcoma. J Biol Chem 254:2600-2609.
22. Maibenco HC, Krehbiel RH, Nelson D. 1967. Transplantable osteogenic tumor in the rat. Cancer Res 27:362-366.
23. Murphey MD, Walker EA, Wilson AJ, et al. 2003. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics 23:1245-1278.
24. David E, Blanchard F, Heymann MF, et al. 2011. The bone niche of chondrosarcoma: a sanctuary for drug resistance, tumour growth and also a source of new therapeutic targets. Sarcoma 2011: 932451. 1-8.
25. Ebetino FH, Hogan AM, Sun S, et al. 2011. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 49: 20-33.
26. Suva LJ, Washam C, Nicholas RW, et al. 2011. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7:208-218.
27. Oji GS, Gomez P, Kurriger G, et al. 2007. Indian hedgehog signaling pathway differences between swarm rat chondro-sarcoma and native rat chondrocytes. Iowa Orthop J 27:9-16.
28. Miot-Noirault E, David E, Vidal A, et al. 2013. 99mTc-NT P 15-5 assessment of the early therapeutic response of chon-drosarcoma to zoledronic acid in the Swarm rat orthotopic model. EJNMMI Res 3:40.